Table 3.
Clinical outcomes
| Outcome | IVIG Only
|
IVIG/PP
|
|
|---|---|---|---|
| Group 1, Weak/Moderate DSA (n = 12) | Group 2, Strong DSA (n = 9) | Group 3, Strong DSA (n = 14) | |
| Follow-up (mo; median [range]) | 16 (8 to 35) | 22 (8 to 31) | 12 (6 to 18) |
| Patient survival (%) | 100 | 100 | 93 |
| Graft survival (%) | 100 | 78 | 86 |
| Acute rejection (%) | 0 | 66 | 7 |
| AMR | 0 | 44 | 7 |
| ACR | 0 | 22 | 0 |
| Biopsy-proven CAN (%) | 0 | 44 | 14 |
| Median Cr (mg/dl; median [range]) | 1.1 (0.6 to 2.8) | 1.2 (1.0 to 4.5) | 1.2 (0.7 to 1.9) |
| Patients with Cr <2.0 (%) | 92 | 71 | 100 |
| Patients with Cr <1.4 (%) | 75 | 71 | 71 |
| CMV disease (%) | 8 | 11 | 0 |
| Polyoma nephropathy (%) | 0 | 0 | 7 |
| Proteinuria (%) | 0 | 11 | 7 |
aCr, serum creatinine level.